Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_3
3
60%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Other(3)

Detailed Status

unknown3
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed120%
unknown360%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

NCT07062978
unknownphase_3

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

NCT04550949
unknownphase_1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

NCT04213105
unknownphase_3

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

NCT04128163
completedphase_1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

NCT03651947

Clinical Trials (5)

Showing 5 of 5 trials
NCT07062978Phase 3

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Recruiting
NCT04550949Phase 3

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Unknown
NCT04213105Phase 1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Unknown
NCT04128163Phase 3

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Unknown
NCT03651947Phase 1

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5